

Listing of Claims

The following list of claims will replace all prior versions and listings of claims in the application.

1-15. (Canceled)

16. (Currently Amended) A method of ~~treating~~ reducing endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need of ~~such treatment~~ thereof,
wherein said endothelial injury is caused by ~~mechanical damage, inflammation or heart disease~~ a chemotherapeutic agent.

17-21. (Canceled)

22. (Previously Presented) A method according to claim 16, wherein said erythropoietin is administered intravenously.

23-30 (Canceled)

31. (Currently Amended) A method of treating endothelial injury in a subject, comprising intravenously administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,

wherein said effective endothelial-protecting amount of erythropoietin reduces or prevents the suppression of endothelial growth associated with endothelial injury caused by ~~mechanical damage, inflammation or heart disease~~ a chemotherapeutic agent.

32. (Currently Amended) A method of treating endothelial injury in a subject, comprising intravenously administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,

wherein said effective endothelial-protecting amount of erythropoietin increases the numbers of viable endothelial cells following endothelial injury caused by ~~mechanical damage, inflammation or heart disease~~ a chemotherapeutic agent.

33. (Previously Presented) A method according to claim 16, wherein said erythropoietin is administered in an amount of from about 100 Units per kilogram to about 200 Units per kilogram.

34-40. (Canceled)

41. (New) A method of claim 16, wherein said erythropoietin is administered prior to administration of said chemotherapeutic agent.

42. (New) A method of claim 16, wherein said chemotherapeutic agent is cisplatin.

43. (New) A method of reducing endothelial injury in a subject, comprising intravenously administering an effective endothelial-protecting amount of erythropoietin to said subject in need thereof,

wherein said endothelial injury is caused by cisplatin and said erythropoietin is administered in an amount less than about 750 U/kg and prior to administration of said cisplatin.